Stephen Hahn, director of the U.S. Food and Drug Administration (FDA), spoke about the agency’s ongoing work, including potential treatments and vaccine development for the new coronavirus, which is currently spreading globally,media reported. Although the White House said in a statement Thursday that antimalarial chloroquine, a drug that has been approved by the FDA, will treat new coronary pneumonia, Hahn said, while the agency is currently looking for extensive clinical trials of the drug but has not yet approved its use.
Another drug that Hasseenhasi, which has shown potential positive potential, has also been described by Trump as “very close” to FDA approval. In response, Hahn clarified that Redciewe is currently conducting clinical trials, a standard FDA-approved process for the use of clinical treatmentin in the United States. When asked if the drug would be commercially available, Hahn declined to comment on the agency’s ongoing business arrangements with Reddit manufacturer Gilead.
In addition, Hahn highlighted the possibility of another experimental treatment being studied by the FDA: using plasma extracted from the blood of recovered new coronal patients and injecting them into other patients in an attempt to activate their own immune responses.
Hahn noted that all treatments currently approved by the FDA for other diseases are available to medical professionals for charitable use. This provision allows doctors to use these drugs in new crown patients, and the advantage of this compassionate pattern of use is that doctors who take advantage of this need to share all patient information about administration and response to the drug, which helps inform ongoing trials and management.
Since the beginning of the new coronal pandemic, a large number of clinical studies on chloroquine and ridsiewewehavean have been conducted worldwide. A recent study in France included the use of a chloroquine variant called hydroxychloroquine, which found that it worked particularly well with an antibiotic called aziamycin. Still, Hahn said, even if a drug has been approved for other purposes, it is critical for researchers to determine the right dose to protect the patient’s health, which is critical to the safe deployment of any treatment.